Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
9.03
-0.53 (-5.54%)
Mar 31, 2025, 1:22 PM EDT - Market open
Entrada Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Entrada Therapeutics stock have an average target of 25.67, with a low estimate of 20 and a high estimate of 29. The average target predicts an increase of 184.27% from the current stock price of 9.03.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Entrada Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 4 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +121.48% | Mar 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +121.48% | Feb 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +121.48% | Feb 4, 2025 |
| Roth MKM | Roth MKM | Strong Buy Initiates $29 | Strong Buy | Initiates | $29 | +221.15% | Dec 5, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $25 → $28 | Buy | Maintains | $25 → $28 | +210.08% | Nov 6, 2024 |
Financial Forecast
Revenue This Year
43.13M
from 210.78M
Decreased by -79.54%
Revenue Next Year
39.58M
from 43.13M
Decreased by -8.22%
EPS This Year
-3.07
from 1.68
EPS Next Year
-3.35
from -3.07
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 63.0M | 63.0M | 89.3M | ||
| Avg | 43.1M | 39.6M | 50.5M | ||
| Low | 19.6M | n/a | 6.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -70.1% | 46.1% | 125.5% | ||
| Avg | -79.5% | -8.2% | 27.5% | ||
| Low | -90.7% | - | -82.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.24 | -2.08 | -1.62 |
| Avg | -3.07 | -3.35 | -3.25 |
| Low | -3.68 | -4.41 | -4.41 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.